Posting of Shareholder Circular

RNS Number : 0341K
Circassia Pharmaceuticals Plc
10 December 2018
 

CIRCASSIA PHARMACEUTICALS PLC

POSTING OF SHAREHOLDER CIRCULAR

Oxford, UK - 10 December 2018: Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that further to the announcement earlier today, a Circular has been published and will be posted to shareholders today in relation to the proposed cancellation of ordinary shares from the Official List and Admission to trading on AIM. The Circular contains the notice convening the General Meeting to be held at the offices of Circassia Pharmaceuticals plc, Northbrook House, Robert Robinson Avenue, The Oxford Science Park, Oxford, Oxfordshire, OX4 4GA, United Kingdom at 12 midday on 4 January 2019.

A copy of the Circular will shortly be available on the Company's website at www.circassia.com.

Enquiries

Circassia

 

Steve Harris, Chief Executive Officer

Tel: +44 (0) 1865 405 560

Julien Cotta, Chief Financial Officer

 

Rob Budge, Corporate Communications

 

 

 

Peel Hunt

 

James Steel / Dr. Christopher Golden

Tel: +44 (0) 20 7418 8900

 

 

Numis Securities

 

James Black / Freddie Barnfield

Tel: +44 (0) 20 7260 1000

 

 

FTI Consulting

 

Simon Conway / Mo Noonan

Tel: +44 (0) 20 3727 1000

About Circassia

Circassia is a world-class specialty pharmaceutical business focused on respiratory disease.  Circassia sells its novel, market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom and Germany, and in a wide range of other countries through its network of partners.  In 2017, the Company established a commercial collaboration with AstraZeneca in the United States in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza® and has the commercial rights to NDA-stage COPD product Duaklir®.  For more information please visit www.circassia.com.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CIRURVBRWSAUAAA

Companies

Niox Group (NIOX)
UK 100

Latest directors dealings